Continued improvement in myocardial T2* over two years of deferasirox therapy in β-thalassemia major patients with cardiac iron overload

Dudley J. Pennell, John B. Porter, Maria Domenica Cappellini, Lee Lee Chan, Amal El-Beshlawy, Yesim Aydinok, Hishamshah Ibrahim, Chi Kong Li, Vip Viprakasit, Mohsen Saleh Elalfy, Antonis Kattamis, Gillian Smith, Dany Habr, Gabor Domokos, Bernard Roubert, Ali Taher

Research output: Contribution to journalArticlepeer-review

Abstract

Background The efficacy of cardiac iron chelation in transfusion-dependent patients has been demonstrated in one-year prospective trials. Since normalization of cardiac T2* takes several years, the efficacy and safety of deferasirox was assessed for two years in patients with β-thalassemia major in the cardiac sub-study of the EPIC trial. Design and Methods Eligible patients with myocardial T2* greater than 5 to less than 20 ms received deferasirox, with the primary endpoint being the change in T2* from baseline to two years. Results Baseline myocardial T2* was severe (>5 to

Original languageEnglish
Pages (from-to)48-54
Number of pages7
JournalHaematologica
Volume96
Issue number1
DOIs
Publication statusPublished - Jan 2011

Keywords

  • β-thalassemia major
  • Cardiac iron overload
  • Deferasirox
  • Iron chelation
  • Myocardial T2*

ASJC Scopus subject areas

  • Hematology

Fingerprint

Dive into the research topics of 'Continued improvement in myocardial T2* over two years of deferasirox therapy in β-thalassemia major patients with cardiac iron overload'. Together they form a unique fingerprint.

Cite this